A Phase 1, Randomized, Placebo-Controlled, Observer-Blind Study to Evaluate the Safety, Tolerability and Immunogenicity of Heterologous and Homologous Prime-Boost Regimens Using MVA-BN-Filo and Ad26.ZEBOV Administered in Different Sequences and Schedules in Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 16 Jun 2017
At a glance
- Drugs Ad26 EBOV vaccine (Primary) ; Modified Vaccinia Ankara Bavarian Nordic Ebola Marburg vaccine (Primary)
- Indications Ebola virus infections; Marburg virus disease
- Focus Adverse reactions
- Sponsors Janssen Infectious Diseases BVBA; Janssen Vaccines and Prevention
- 12 Jun 2017 Status changed from active, no longer recruiting to completed.
- 30 Sep 2016 Status changed from recruiting to active, no longer recruiting.
- 18 Aug 2016 Status changed from active, no longer recruiting to recruiting.